October 27, 2020 : Issue #1075

DISASTERS AVERTED — Near Miss Case Studies

Using Newer Glucagon Products

TOP STORIES — Diabetes News and Research

Associations between Prediabetes and Vascular Complications

Dulaglutide Can Reduce Cognitive Impairment in Patients with T2D

Prolonged Use of Proton Pump Inhibitors Linked to Increased Risk of T2DM

MOST POPULAR ARTICLES OF THE MONTH

#1 Pumping Up with Protein: Does This Work for Exercise and Health?</p >

#2 The Promising Future of Oral Insulin

#3 Possible Link Connecting COVID-19 and New-Onset Diabetes

I don’t often get to watch commercials on TV since I nixed the cable, but when I travel I often put on the news and the commercials come flying at me. Over the past two weeks I have gotten an education on the lawsuits I can be part of if I ever took a proton pump inhibitor.

The announcers talk about kidney failure and cancers, and ask you to join them in their class action suit.

Now, based on a study from our University of Colorado intern, Arjay Mendoza, we can add increased type 2 diabetes risk to the list of problems. Read his research to learn just how bad it can be.

*****************************

We can make a difference!

*****************************

Dave Joffe

Editor-in-chief

Newer glucagon products provide additional options for the treatment of severe hypoglycemia.

We were asked to consult on a case involving a 68-year-old man with type 1 diabetes (T1D). He recently experienced a severe hypoglycemic event resulting in hospitalization. The patient currently lives independently with his wife of 40 years and has had T1D since the age of 12….

Do patients with prediabetes share the same vascular complication risk seen in patients with T2D?

A recent exploratory analysis of the REWIND trial evaluated a potential additive benefit to using a once-weekly GLP-1 RA.

Long-term users of the acid reflux drugs known as Proton Pump Inhibitors (PPIs) have a 24% higher risk of developing type 2 diabetes than non-PPI users.